Pure Global
NCT06419361

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

First Affiliated Hospital of Chongqing Medical University·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Stimulator of Interferon Gene,Cancer,Positron Emission Tomography
Drug/Device/Intervention
[68Ga]Ga-Sa-DABI-4
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
First Affiliated Hospital of Chongqing Medical University
Location
Chongqing, China
Timeline & enrollment
Phase
Phase 1
Start date
May 21, 2024
End date
Dec 31, 2026
Enrollment
30 participants
Primary outcome

Diagnostic efficacy

Summary

Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance
 of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING
 therapy. This study will investigate the safety, biodistribution and potential usefulness of
 a novel 68Ga-labeled agonist ([68Ga]Ga-Sa-DABI-4) for noninvasive positron emission
 tomography (PET) imaging of STING expression in the tumor microenvironment.

ICD-10 classifications
Erythema intertrigo
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419361
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419361 through Pure Global AI's free database. This Phase 1 trial is sponsored by First Affiliated Hospital of Chongqing Medical University and is currently Not yet recruiting. The study focuses on Stimulator of Interferon Gene,Cancer,Positron Emission Tomography. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.